Clinical trial
Seroquel in Bipolar Depression Versus SSRI
NCT00119652 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00119652 |
|---|---|
| Title | Seroquel in Bipolar Depression Versus SSRI |
| Official title | Multicentre, Double-blind, Randomised, Parallel Group, Placebo Controlled, Phase 3 Study of the Efficacy & Safety of Quetiapine Fumarate & Paroxetine as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks & Quetiapine in Continuation (Abbreviated) |
| Acronym | EMBOLDEN II |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bipolar Disorder, Bipolar Depression, Depression |
| Intervention type | Behavioral, Drug |
| Interventions | quetiapine fumarate (Seroquel), paroxetine, mood stabilizing activity |
| Enrollment | 676 |
| Start date | May 1, 2005 |
| Completion | May 1, 2007 |
| First posted | Jul 14, 2005 |
| Last update posted | Jan 4, 2013 |
| Countries | Australia, Chile, Colombia, Costa Rica, Greece, Mexico, Peru, Romania, South Africa, Turkey (Türkiye), United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: